Real-World Outcomes of Axicabtagene Ciloleucel for Treatment of Relapsed or Refractory Large B-Cell Lymphoma in Canada

CD19 CAR T-cell therapy has significantly improved the survival of patients with relapsed or refractory large B cell lymphoma (R/R LBCL) and is considered standard of care for eligible patients in Canada. Axicabtagene ciloleucel (axi-cel) is an autologous CAR T-cell therapy, initially approved by He...

Description complète

Détails bibliographiques

Auteurs principaux:	Christopher Lemieux, John Kuruvilla, Mona Shafey, Kelly Davison, Kristjan Paulson, Sue Z. L. Li, Lieven Billen, Francis Nissen, Hai-Lin Wang, Jenny J. Kim, Grace Lee, Zhen-Huan Hu, Brent Logan, Zhongyu Feng, Marcelo C. Pasquini, Kevin Hay
Format:	Artigo
Langue:	Inglês
Publié:	MDPI AG 2026-01-01
Collection:	Current Oncology
Sujets:	axicabtagene ciloleucel axi-cel CAR T large B-cell lymphoma LBCL real-world registry
Accès en ligne:	https://www.mdpi.com/1718-7729/33/2/85
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!